	US 11,788,072 B2
	Activation of APC in immunotherapy
Chengfei Pu, Shanghai (CN); Lei Xiao, Rockville, MD (US); He Sun, Shanghai (CN); Xiaogang Shen, Shanghai (CN); and Cheng Lu, Shanghai (CN)
Assigned to Innovative Cellular Therapeutics Holdings, Ltd., George Town (KY)
Filed by Innovative Cellular Therapeutics Holdings, Ltd., Grand Cayman (KY)
Filed on Apr. 29, 2020, as Appl. No. 16/861,993.
Claims priority of provisional application 62/880,298, filed on Jul. 30, 2019.
Claims priority of provisional application 62/878,067, filed on Jul. 24, 2019.
Claims priority of provisional application 62/840,985, filed on Apr. 30, 2019.
Prior Publication US 2020/0347367 A1, Nov. 5, 2020
Int. Cl. C12N 9/12 (2006.01); C07K 14/725 (2006.01); C07K 14/47 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 35/17 (2015.01)

CPC C12N 9/12 (2013.01) [A61K 35/17 (2013.01); A61P 35/00 (2018.01); C07K 14/4748 (2013.01); C07K 14/7051 (2013.01); C07K 16/2803 (2013.01); C12Y 207/10001 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01)]

18 Claims

1. An isolated polynucleotide comprising a polynucleotide encoding a nuclear factor of activated T cells (NFAT) promoter operatively linked to a polynucleotide encoding Fms-related tyrosine kinase 3 ligand (FLT3L), wherein the polynucleotide comprises SEQ ID NO: 133 or 134.